Society of Thoracic Surgeons - Surgeon

NOVEMBER 3, 2023

While both trials showed similar results, there are important differences in design, demographics, and patients’ outcomes. Plan to attend Part 2 on Thursday, December 14, titled " Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC." Moderators Robert E. Merritt, MD The Ohio State University Columbus, OH Sandra L.

Cancer 52

Cancer Webinar Biomarkers Hospital 52

DAIC

JUNE 4, 2024

I am excited about the potential of the FAI-Score biomarker, which has promising prognostic value beyond existing CT-based methods such as plaque, calcium scoring, and CAD-RADS based interpretation." Details of the study, included in a written statement issued by Caristo Diagnostics, follow. fold higher risk for cardiac mortality and 5.5-fold

Technology 116

Technology Heart attacks Heart Attack Coronary Artery Disease 116

Dr. Smith's ECG Blog

JUNE 18, 2013

These patients have worse outcomes: higher mortality, more CHF, higher biomarkers, and worse ejection fractions than the NonSTEMI patients with open arteries. Incidence Incidence, angiographic features and outcomes of patients presenting with subtle ST-elevation myocardial infarction. This is because of subtle ECG findings.

STEMI 52

STEMI Chest Pain Myocardial Infarction Webinar 52